NL-OMON48072
Completed
Not Applicable
A study evaluating the pharmacokinetics, safety and tolerability of OP2113 administered intravenously in healthy volunteers and a marketed formulation administered orally - OP2-CS-001 OP2 Drugs
OP2 Drugs0 sites12 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- OP2 Drugs
- Enrollment
- 12
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male and female subjects aged between 18 and 65 years (inclusive) with
- •a body mass index (BMI) of \*18\.0 kg/m2 and \* 30\.0 kg/m2 (inclusive) at
- •Further inclusion criteria can be found in the protocol section 8\.4\.1
Exclusion Criteria
- •Relevant prior or ongoing medical condition that, in the Investigator\*s
- •opinion, could adversely affect the safety of the subject.
- •History of clinically\-significant hypersensitivity to any of the study drugs,
- •excipients or materials used to administer the study medication.
- •Further exclusion criteria can be found in the protocol section 8\.4\.2
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A study to evaluate the pharmacokinetics, safety and tolerability after inhalation of MMI-0100 in healthy subjects; MMI-0100 is an investigational drug developed for the treatment of fibrotic indications.idiopathische fibroseIdiopathic pulmonary fibrosispulmonary diseases.NL-OMON40896Moerae Matrix, Inc48
Completed
Not Applicable
The aim of this study is to compare and evaluate the pharmacokinetic properties and safety of oral administration of test drugEndocrine, nutritional and metabolic diseasesKCT0004026Kyung Dong Pharmaceutical80
Active, not recruiting
Not Applicable
Study to evaluate the safety and pharmacokinetics of ciprofloxacin following inhalation of ciprofloxacin dry powder for inhalation administered to pediatric patients with cystic fibrosis aged 12-17 yearslong term treatment of chronic lung infections caused by Pseudomonas aeruginosa in patients with cystic fibrosisMedDRA version: 8.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungEUCTR2007-002912-24-DEBayer HealthCare AG16
Recruiting
Phase 1
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors-JPRN-jRCT2080225128-6
Not yet recruiting
Phase 1
Safety and pharmacokinetics of CIGB-552Solid tumorsRPCEC00000196Center for Genetic Engineering and Biotechnology (CIGB)